Dr. Reddys Laboratories is currently trading at Rs. 3593.55, up by 10.50 points or 0.29% from its previous closing of Rs. 3583.05 on the BSE.
The scrip opened at Rs. 3572.00 and has touched a high and low of Rs. 3610.80 and Rs. 3563.95 respectively. So far 5948 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4382.95 on 20-Oct-2015 and a 52 week low of Rs. 2750.00 on 21-Jan-2016.
Last one week high and low of the scrip stood at Rs. 3633.00 and Rs. 3554.40 respectively. The current market cap of the company is Rs. 61128.28 crore.
The promoters holding in the company stood at 25.58%, while Institutions and Non-Institutions held 42.02% and 32.40% respectively.
Dr. Reddy’s Laboratories has launched Omeprazole and Sodium bicarbonate capsules, 20mg/1100mg and 40mg/1100mg, a therapeutic equivalent generic version of ZEGERID (omeprazole/sodium bicarbonate) capsules in the United States market, having been approved by the U.S. Food & Drug Administration (USFDA).
The Zegeride brand and generic had U.S. sales of around $306.7 million MAT for the most recent twelve months ending in May 2016. The company’s Omeprazole and sodium bicarbonate capsules 20 mg/1100 mg and 40 mg/1100 mg are available in bottle count size of 30. Zegerid is a registered trademark of Santarus, Inc. a wholly owned subsidiary of Salix Pharmaceuticals, Inc.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1877.25 |
| Dr. Reddys Lab | 1287.65 |
| Cipla | 1335.20 |
| Zydus Lifesciences | 946.45 |
| Lupin | 2242.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: